fbpx

Elicera – Pre-clinical proof-of-concept data for iTank

Elicera - Pre-clinical proof-of-concept data for iTank 20 OktoberOkt 2021 11:00 - 11:20Online Event

Elicera – Pre-clinical proof-of-concept data for iTank

Please join this event with Elicera’s CDO Dr. Di Yu where he will present pre-clinical proof-of-concept data for the company’s technology platform I-TANK.
Data will be released the October the 19th.

The I-TANK platform has been developed to improve the function of CART cells but also to activate a separate attack by the immune system against the entire set of relevant targets on cancer cells via the patient's own so-called killer T-cells," says CEO Jamal El-Mosleh. “We use the technology to strengthen our own drug candidates, including next generation of oncolytic viruses, which is why it is considered one of our most important assets.

The company develops four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields.

Deltag her

Du vil blive videresendt til en ekstern tilmeldingsside. 

Information

Elicera - Pre-clinical proof-of-concept data for iTank 20 OktoberOkt 2021 11:00 - 11:20
Elicera - Pre-clinical proof-of-concept data for iTank Online Event
Elicera Therapeutics
Elicera - Pre-clinical proof-of-concept data for iTank 20 OktoberOkt 2021 11:00 - 11:20Online Event

Elicera – Pre-clinical proof-of-concept data for iTank

Please join this event with Elicera’s CDO Dr. Di Yu where he will present pre-clinical proof-of-concept data for the company’s technology platform I-TANK.
Data will be released the October the 19th.

The I-TANK platform has been developed to improve the function of CART cells but also to activate a separate attack by the immune system against the entire set of relevant targets on cancer cells via the patient's own so-called killer T-cells," says CEO Jamal El-Mosleh. “We use the technology to strengthen our own drug candidates, including next generation of oncolytic viruses, which is why it is considered one of our most important assets.

The company develops four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields.

Information

Elicera - Pre-clinical proof-of-concept data for iTank 20 OktoberOkt 2021 11:00 - 11:20
Elicera - Pre-clinical proof-of-concept data for iTank Online Event
Elicera Therapeutics